Breakthrough antiviral research targets HIV, H1N1 and beyond with novel therapies
Scientists from the Heinrich Pette Institute and the University Medical Center Hamburg-Eppendorf are collaborating on a promising path to combat viral infections. Their research focuses on novel antiviral drugs, including new antiretroviral classes and a unique enzyme to remove HIV from infected cells. The innovative approach could protect unvaccinated individuals, lessen disease severity, and control the spread of respiratory and emerging viruses.
The influenza virus's genome consists of eight distinct segments that interact like a liquid, allowing each segment to find its partners. Researchers are exploring this property to develop antivirals that could halt viral replication by disrupting these interactions. Dissolving or hardening these condensates could prevent the virus from assembling its genome, blocking infection.
Portuguese researchers are testing a method to block the H1N1 virus before infection. This innovative strategy aims to overcome current antiviral limitations by identifying new viral targets. The goal is to create broad-spectrum therapies effective against multiple respiratory viruses, including HIV, Zika, herpes simplex, and hemorrhagic viruses where vaccines are not available.
The collaborative research between basic scientists and clinicians is a promising step towards expanding therapeutic options against viral infections. By targeting the influenza virus's genome and exploring new antiviral strategies, scientists aim to protect unvaccinated individuals, lessen disease severity, and prevent future epidemics.
